Fig. 3 | Cellular & Molecular Immunology

Fig. 3

From: A de novo missense mutation in MPP2 confers an increased risk of Vogt–Koyanagi–Harada disease as shown by trio-based whole-exome sequencing

Fig. 3

The effects of MPP2 mutation in ARPE19 cells with MPP2 deletion. A, B The KO efficiency of MPP2 and overexpression level of MPP2 wild-type or the MPP2 mutant (n = 3/group; mean ± SD; ***p < 0.001; one-way ANOVA). C The proliferation of ARPE19 cells with vehicle, MPP2 KO or overexpression of MPP2 mutant lentiviruses after MPP2 deletion (n = 5/group; mean ± SD; **p < 0.01; one-way ANOVA). D–F The secretion levels of inflammatory factors including IL-1β, VEGFA and IL-10 by ELISA kits (n = 6/group; mean ± SD; NS > 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA). G The electrical resistance of ARPE19 cells with vehicle, MPP2 KO or overexpression of MPP2 mutant lentiviruses after MPP2 deletion (n = 3/group; mean ± SD; *p < 0.05, ***p < 0.001; one-way ANOVA). H The phenol red leakage of ARPE19 cells with vehicle, MPP2 KO or overexpression of MPP2 mutant lentiviruses after MPP2 KO (n = 5/group; mean ± SD; **p < 0.01, ***p < 0.001; one-way ANOVA). I Images of transmission electron microscope (TEM) in the four groups mentioned above (scale bar, 1 μm). J The immunofluorescence results of ZO-1 (scale bar, 50 μm). K, L The protein expression and quantification of ZO-1 (n = 3/group; mean ± SD; *p < 0.05, **p < 0.01; one-way ANOVA)

Back to article page